Bild/Picture ®Thomas Ferber/Oncoletter

  • Oral Abstract Session - Immunotherapy
  • Poster Discussion Session - Immunotherapy
  • Rapid Abstract Session - Immunotherapy
  • Traversing Toxicities of Immuno-Oncology Agents - Molecular Predictors and Rational Outcomes
  • The Promise of Neoadjuvant Immunotherapy Across Solid Tumors
  • Oral Abstract Session - Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology
  • Poster Discussion Session - Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology

Oral Abstract Session - Immunotherapy

Initial results from the phase 2A trial of visugromab (CTL-002) + nivolumab in advanced/metastatic anti-PD1/-L1 relapsed/refractory solid tumors (The GDFATHER-TRIAL).

Abstract: 2501: Ignacio Melero Bermejo, Maria J. de Miguel, Guzman Alonso, et al.

Presenter: IGNACIO MELERO BERMEJO

Zusammenfassung folgt

--------------------------------------------------------------------------------------------------------------------------

Initial results from a first-in-human, phase I study of immunomodulatory aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 in patients with advanced solid tumors.

Abstract: 2502: Ecaterina Dumbrava, Michael Cecchini, Jon Zugazagoitia, et al.

Presenter: Ecaterina Elena Dumbrava MD

Zusammenfassung folgt

--------------------------------------------------------------------------------------------------------------------------

Tumor mutational burden (TMB) measurement from an FDA-approved assay and real-world overall survival (rwOS) on single-agent immune checkpoint inhibitors (ICI) in over 8,000 patients across 24 cancer types.

Abstract: 2503:David Gandara, Neeraj Agarwal, Shilpa Gupta, et al.

Presenter: David R. Gandara, MD, FASCO

Zusammenfassung folgt

--------------------------------------------------------------------------------------------------------------------------

Evaluation of change in RECIST tumor size and survival in patients with rare cancers treated with checkpoint inhibitor therapy (SWOG S1609).

Abstract: 2504: Megan Othus, Sandip Patel, Young Kwang Chae, et al.

Presenter: Megan Othus

Zusammenfassung folgt

--------------------------------------------------------------------------------------------------------------------------

Interim update of the ATRC-101 phase 1b trial in advanced solid tumors.

Abstract: 2505: Bartosz Chmielowski, Saravut Weroha, Susanna Ulahannan, et al.

Presenter: Bartosz Chmielowski, MD, PhD

Zusammenfassung folgt

--------------------------------------------------------------------------------------------------------------------------

Phase I study of the bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 combined with SHR2554, an EZH2 inhibitor, in patients with previously treated advanced lymphoma and solid tumors.

Abstract: 2507: Kaichao Feng, Yang Liu, Chunmeng Wang, et al.

Presenter: Kaichao Feng

Zusammenfassung folgt

--------------------------------------------------------------------------------------------------------------------------

Phase 1/2 Study of DF1001, a novel tri-specific, NK cell engager therapy targeting HER2, in patients with advanced solid tumors: Phase 1 DF1001 monotherapy dose-escalation results.

Abstract: 2508: Howard Safran, Philippe Cassier, Cecile Vicier, et al.

Presenter: Howard Safran MD

Zusammenfassung folgt

--------------------------------------------------------------------------------------------------------------------------

To watch the Presentation and Discussion of this Oral Abstract Session, you need an ASCO Annual Meeting registration.

--------------------------------------------------------------------------------------------------------------------------

POSTER SESSION:

Developmental Therapeutics—Immunotherapy

Poster Discussion Session - Immunotherapy

Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501/501A in relapsed/refractory large B-cell lymphoma (r/r LBCL).

Abstract: 2517 | Poster Bd #: 359: Frederick Locke, Lazaros Lekakis, Herbert Eradat, et al.

Presenter: Frederick L. Locke MD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

CLDN6 CAR-T cell therapy of relapsed/refractory solid tumors ± a CLDN6-encoding mRNA vaccine: Dose escalation data from the BNT211-01 phase 1 trial using an automated product.

Abstract: 2518 | Poster Bd #: 360: Andreas Mackensen, John Haanen, Christian Koenecke, et al.

Presenter: Andreas Mackensen, MD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors.

Abstract: 2519 | Poster Bd #: 361: Benjamin Schlechter, Daniel Olson, Mridula George, et al.

Presenter: Benjamin L. Schlechter, MD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

A phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via intratumoral (IT) injection as monotherapy in advanced solid tumors.

Abstract: 2520 | Poster Bd #: 362: Dongmei Ji, Yao Weitao, Xiangmin Tong, et al.

Presenter: Dongmei Ji MD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

Safety and early biologic effects of phase 1 PERIO-01 trial of pressure-enabled drug delivery (PEDD) of TLR9 agonist SD-101 and immune checkpoint inhibition (ICI) in uveal melanoma metastatic to the liver (MUM).

Abstract: 2521 | Poster Bd #: 363:Kamaneh Montazeri, Diwakar Davar, Cara Haymaker, et al.

Presenter: Kamaneh Montazeri MD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

The immune microenvironment in hormone positive, HER2 negative breast cancer: A focus on tumour infiltrating lymphocytes, spatial phenotypes and tertiary lymphoid structures.

Abstract: 2522 | Poster Bd #: 364: Mairi Lucas, Zak Kinsella, Claudia Gonzalez, et al.

Presenter: Mairi Lucas MBChB

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

A phase 1a dose-escalation study of PY159, a monoclonal antibody targeting TREM1 (triggering receptor expressed on myeloid cells 1).

Abstract: 2523 | Poster Bd #: 365: Ira Winer, Amita Patnaik, Minal Barve, et al.

Presenter: Ira Seth Winer MD, PhD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

A phase 1 study of AGEN2373, a novel CD137 agonist antibody designed to avoid hepatoxicity, in patients with advanced solid tumors.

Abstract: 2524 | Poster Bd #: 366: Minal Barve, Anthony Tolcher, Richard Carvajal, et al.

Presenter: Minal A. Barve MD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

First-in-human, phase 1a dose finding of LVGN6051 CD137/4-1BB agonistic antibody with or without pembrolizumab in patients with advanced solid tumors.

Abstract: 2525 | Poster Bd #: 367: Adil Daud, Costantine Albany, Vamsidhar Velcheti, et al.

Presenter: Adil Daud

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors.

Abstract: 2526 | Poster Bd #: 368: Pei Shu, Xiaoyu Li, Li Yuan, Qi Zhou, et al.

Presenter: Pei Shu

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

A phase 1 dose-escalation study of RiMO-301 with palliative radiation in advanced tumors.

Abstract: 2527 | Poster Bd #: 369: Matthew Koshy, Michael Spiotto, Lawrence Feldman, et al.

Presenter: Matthew Koshy MD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

AMPLIFY-201, a first-in-human safety and efficacy trial of adjuvant ELI-002 2P immunotherapy for patients with high-relapse risk with KRAS G12D- or G12R-mutated pancreatic and colorectal cancer.

Abstract: 2528 | Poster Bd #: 370: Eileen O'Reilly, Zev Wainberg, Colin Weekes, et al.

Presenter: Eileen Mary O'Reilly, MD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

To watch the Presentation and Discussion of this Poster Discussion Session, you need an ASCO Annual Meeting registration.

 

Rapid Abstract Session - Immunotherapy

Baseline autoantibody profiling in patients with NSCLC with pre-existing autoimmune diseases or who had received prior anti-PD-1 therapy before enrolling in the TAIL study.

Abstract: 2512 :

Presenter: Delvys Rodriguez-Abreu, MD, PhD

----------------------------------------------------------------------------------------------------------------------

Targeting CD47 in lymphoid malignancies with CAR T cells.

Abstract: 2513 :

Presenter:Alexander Paul Boardman

----------------------------------------------------------------------------------------------------------------------

Association of common inherited NOD2 mutations with exceptional response to immune checkpoint inhibitors.

Abstract: 2514 :

Presenter: Megan Babette Barnet, PhD, BS, MBBS, FRACP

----------------------------------------------------------------------------------------------------------------------

Intestinal microbiome characterization in immune checkpoint inhibition (ICI) resistant disease.

Abstract: 2515 :

Presenter: Pavlina Spiliopoulou, MD, PhD

----------------------------------------------------------------------------------------------------------------------

Association of ctDNA tumor fraction with survival in advanced non-small cell lung cancer (NSCLC) treated with maintenance durvalumab in the UNICANCER SAFIR02-Lung/IFCT1301 trial.

Abstract: 2516:

Presenter: Filippo Gustavo Dall’Olio MD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

To watch the Presentation and Discussion of this Rapid Abstract Session, you need an ASCO Annual Meeting registration.

 

Clinical Science Symposium: Traversing Toxicities of Immuno-Oncology Agents: Molecular Predictors and Rational Outcomes

Clinical and immune phenotypes associated with immune checkpoint inhibitor-induced autoimmune diabetes.

Abstract: 2509:

Presenter: Karina Ruiz-Esteves

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

First-line treatment of fecal microbiota transplantation for immune-mediated colitis.

Abstract: 2510:

Presenter: Yinghong Wang

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

Identifying molecular targets for rational immunosuppressive strategies in patients with immune checkpoint therapy-induced myocarditis and myositis.

Abstract: 2511:

Presenter: Bilal Ahmed Siddiqui MD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

To watch the Presentation and Discussion of this Clinical Science Symposium, you need an ASCO Annual Meeting registration.

 

Clinical Science Symposium: The Promise of Neoadjuvant Immunotherapy Across Solid Tumors

KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.

Abstract: LBA10:

Presenter: Heather A. Wakelee, MD, FASCO

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma: Three-year data of PRADO and OpACIN-neo.

Abstract: 10:

Presenter: Irene L.M. Reijers MD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

Biomarkers predicting response to 5 immunotherapy arms in the neoadjuvant I-SPY2 trial for early-stage breast cancer (BC): Evaluation of immune subtyping in the response predictive subtypes (RPS).

Abstract: 10:

Presenter: Denise Wolf

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

Friendly-user score assessing gut dysbiosis and resistance to immune checkpoint inhibitors (ICI).

Abstract: 103:

Presenter: Lisa Derosa MD, PhD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

To watch the Presentation and Discussion of this Clinical Science Symposium, you need an ASCO Annual Meeting registration.

 

Oral Abstract Session - Molecularly Targeted Agents and Tumor Biology

Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results.

Abstract: LBA3000: Funda Meric-Bernstam, Vicky Makker, Ana Oaknin, et al.

Presenter: Funda Meric-Bernstam, MD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study.

Abstract: 3001: Li Zhang, Yuxiang Ma, Yuangyuan Zhao, et al.

Presenter: Li Zhang, MD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

First-in-human study of ABBV-011, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate, in patients with small cell lung cancer.

Abstract: 3002: Daniel Morgensztern, Neal Ready, Melissa Johnson, et al.

Presenter: Daniel Morgensztern MD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

Detection of peritoneal metastases during cytoreductive surgery using pegsitacianine, a pH sensitive imaging agent: Final results from a phase 2 study.

Abstract: 3003: Patrick Wagner, Edward Levine, Alex Kim, et al.

Presenter: Patrick Wagner, MD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

Methylated DNA biomarkers and incident cancer in the American Cancer Society (ACS) Cancer Prevention Study-3 (CPS-3) cohort.

Abstract: 3004: Alpa Patel, Christina Clarke Dur, Gregory Alexander, et al.

Presenter: Alpa Patel PhD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

Tumor fraction to improve patient selection for oncology early phase clinical trials: Analysis of two precision medicine studies.

Abstract: 3005: Sophie Cousin, Laila Belcaid, Kilian Trin, et al.

Presenter: Sophie Cousin

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

Safety and efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid and CNS tumors: Results from a phase 1/2a study.

Abstract: 3006: Macarena De La Fuente, Jordi Rodon Ahnert, Rona Yaeger, et al

Presenter: Macarena Ines De La Fuente, MD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

A phase I study of KL590586, a next-generation selective RET inhibitor, in patients with RET-altered solid tumors.

Abstract: 3007: Qing Zhou, Yi-Long Wu, Xiangqian Zheng, et al

Presenter: Qing Zhou

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

A phase 1 study of the protein arginine methyltransferase 5 (PRMT5) brain-penetrant inhibitor PRT811 in patients (pts) with recurrent high-grade glioma or uveal melanoma (UM).

Abstract: 3008: Varun Monga, Tanner Johanns, Roger Stupp, et al

Presenter: Varun Monga MBBS

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

To watch the Presentation and Discussion of this Poster Discussion Session, you need an ASCO Annual Meeting registration.

------------------------------------------------------------------------------------------------------------------

POSTER SESSION:

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Poster Discussion Session - Molecularly Targeted Agents and Tumor Biology Primary

First-in-human first-in-class phase 1/2a study of the next generation CDK4-selective inhibitor PF-07220060 in patients (pts) with advanced solid tumors, enriched for HR+ HER2- mBC who progressed on prior CDK4/6 inhibitors and endocrine therapy.

Abstract: 3009 | Poster Bd #: 207: Timothy Yap, Antonio Giordano, Erika Hamilton, et al.

Presenter: Timothy A. Yap MD, PhD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

First-in-human phase 1/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4/6 inhibitor resistant HR+/HER2- breast cancer.

Abstract: 3010 | Poster Bd #: 208: Timothy Yap, Abdelaziz Elhaddad, Rachel Grisham, et al.

Presenter: Timothy A. Yap MD, PhD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

FUTURE-SUPER: A randomized, subtyping-based umbrella phase II trial for first-line treatment of metastatic triple-negative breast cancer.

Abstract: 3011 | Poster Bd #: 209: Shao Zhimin, Lei Fan, Ma Linxiaoxi, et al.

Presenter: Shao Zhimin, MD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

Debio 0123-101: A phase 1 trial of Debio 0123 in combination with carboplatin in advanced solid tumors—Safety, pharmacokinetic, and preliminary antitumor activity data.

Abstract: 3012 | Poster Bd #: 210: Hans Gelderblom, Mathilde Jalving, Ingrid Desar, et al.

Presenter: Hans Gelderblom MD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

Tissue-agnostic efficacy of trastuzumab deruxtecan (T-DXd) in advanced solid tumors with HER2 amplification identified by plasma cell-free DNA (cfDNA) testing: Results from a phase 2 basket trial (HERALD/EPOC1806).

Abstract: 3014 | Poster Bd #: 212: Hiroya Taniguchi, Masataka Yagisawa, Taroh Satoh, et al.

Presenter: Hiroya Taniguchi, MD, PhD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

Dose escalation results from a first-in-human study of ABBV-400, a novel c-Met–targeting antibody-drug conjugate, in advanced solid tumors.

Abstract: 3015 | Poster Bd #: 213: Manish Sharma, Yasutoshi Kuboki, D. Camidge, et al.

Presenter: Manish Sharma MD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant/refractory solid tumors.

Abstract: 3016 | Poster Bd #: 214: Yakun Wang, Jifang Gong, Rongbo Lin, et al.

Presenter: Yakun Wang, PhD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

ARTEMIS-001: Phase 1 study of HS-20093, a B7-H3–targeting antibody-drug conjugate, in patients with advanced solid tumor.

Abstract: 3017 | Poster Bd #: 215: Jie Wang, Jianchun Duan, Ligang Xing, et al.

Presenter: Jianchun Duan

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

Phase 1 trial evaluating TTI-101, a first-in-class, orally bioavailable, small molecule, inhibitor of STAT3, in patients with advanced solid tumors.

Abstract: 3018 | Poster Bd #: 216: Apostolia Tsimberidou, David Vining, Sukeshi Arora, et al.

Presenter: Apostolia Maria Tsimberidou MD, PhD, FASCO

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

Preliminary safety and efficacy of tinengotinib tablets as monotherapy and combination therapy in advanced solid tumors: A phase Ib/II clinical trial.

Abstract: 3019 | Poster Bd #: 217: Sarina Piha-Paul, Sanjay Goel, Chih-Yi Liao, et al.

Presenter: Milind M. Javle MD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

A first-in-human, phase 1 study of the SHP2 inhibitor PF-07284892 as monotherapy and in combination with different targeted therapies in oncogene-driven, treatment-resistant solid tumors.

Abstract: 3020 | Poster Bd #: 218: Alexander Drilon, Melissa Johnson, Shirish Gadgeel, et al.

Presenter: Alexander E. Drilon

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

To watch the Presentation and Discussion of this Poster Discussion Session, you need an ASCO Annual Meeting registration.

 

Dienstleistungen

  • Livecasts
  • Kongress-Berichte
  • Journal-Review
  • Interviews
  • Videos

Impressum

Oncoletter wird über nicht öffentlich zugängliche Werbung für Medizinalpersonen finanziert. Oncoletter finanziert sich zudem mit von Gesundheitsorganisationen (z.B. Universitätsspital, Swiss Academy of Multidisciplinary Oncology SAMO), Stiftungen (z.B. SONK St.Gallen Oncology Conferences) beauftragten Aufnahmen ganzer Kongresse oder Symposien. Weiter erhält Oncoletter nicht an inhaltliche Bedingungen geknüpfte Unterstützung von Firmen zur Berichterstattung. Seit der Inbetriebnahme von Oncoletter haben folgende Firmen die Webseite vorübergehend/permanent und in wechselnden Zusammensetzungen (jährlich 4-6) unterstützt: Amgen, BMS, Celgene, GSK, Janssen-Cilag, Lilly, Merck, Mundipharma, Novartis, Pfizer, Roche, Servier.
Die Inhalte der Website von Oncoletter sind strikt redaktionell und widerspiegeln die Meinungen und Ansichten der Autoren. Bei ausnahmsweise bezahlten Beiträgen oder Interviews (ausschliesslich on-label) wird der Sponsor im Text oder Abspann aufgeführt.

Kontakt

Oncoletter
DR. MED. THOMAS FERBER
CH-8200 SCHAFFHAUSEN

info[@]oncoletter.ch

Copyright 2023. All Rights Reserved.
You are using an outdated browser. The website may not be displayed correctly. Close